
Ireland-headquartered drugmaker Shire (LSE: SHP) says it will acquire San Diego, USA-based rare disease focussed company Lumena Pharmaceuticals for an upfront payment of $260 million in cash, plus a payment for net cash at closing, and near-term contingent milestone payments related to ongoing clinical trials.
The transaction will add to Shire's rare diseases portfolio and leverages this expertise, and is a perfect combination with Shire's already strong gastrointestinal (GI) presence, the UK firm said. Shire does not expect the acquisition of Lumena to result in a change to its previously-stated earnings guidance for 2014 and has not said when it expects the deal to complete.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze